David Moller has joined Sigilon Therapeutics to become the company’s chief scientific officer. Moller comes to the Cambridge, MA, drug developer from Eli Lilly (NYSE: LLY), where he was vice president of business development for emerging technology and innovation. Last year, Sigilon raised $23.5 million in a Series A financing round to bring its technology for encapsulating therapeutic proteins into clinical testing.
Xconomy Insight · Special Report
Industry experts explain what it takes to launch a new biotech company
Sponsored · Special Report
Hyperinflation in rents is over
Hughes Marino
From Our Editors · Podcast
The AI, Big Data, and R&D Boom
